NASDAQ:ERAS

Erasca (ERAS) Stock Forecast, Price & News

$2.71

+0.09 (+3.44%)

(As of 05/31/2023 ET)

Compare

Today's Range: $2.59
▼
$2.74
50-Day Range: $2.57
▼
$3.15
52-Week Range: $2.49
▼
$10.74

Volume: 740,612 shs
Average Volume: 937,893 shs
Market Capitalization: $408.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.33

Erasca MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 318.2% Upside
$11.33 Price Target
Short Interest: Bearish
12.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$339,200 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.29) to ($1.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

325th out of 1,006 stocks

Pharmaceutical Preparations Industry

149th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Erasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.33, Erasca has a forecasted upside of 318.2% from its current price of $2.71.
Amount of Analyst Coverage
Erasca has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
12.52% of the float of Erasca has been sold short.
Short Interest Ratio / Days to Cover
Erasca has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Erasca has recently decreased by 9.22%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Erasca does not currently pay a dividend.
Dividend Growth
Erasca does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ERAS.

2.0

News and Social Media Coverage

News Sentiment
Erasca has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Erasca this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for ERAS on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Erasca insiders have bought more of their company's stock than they have sold. Specifically, they have bought $339,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
37.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.75% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Erasca are expected to decrease in the coming year, from ($1.29) to ($1.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Erasca is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Erasca is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Erasca has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Erasca (NASDAQ:ERAS) Stock

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Stock News Headlines

May 31, 2023 | finance.yahoo.com

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 25, 2023 | finance.yahoo.com

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

June 1, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 25, 2023 | msn.com

Erasca Earnings Preview

May 25, 2023 | finance.yahoo.com

With 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interest

May 16, 2023 | 247wallst.com

Goldman Sachs Maintains Erasca Buy Recommendation

May 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Erasca (ERAS)

May 16, 2023 | msn.com

Goldman Sachs Maintains Erasca (ERAS) Buy Recommendation

June 1, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

May 16, 2023 | markets.businessinsider.com

Erasca (ERAS) Receives a Buy from Goldman Sachs

May 16, 2023 | finance.yahoo.com

Erasca Further Strengthens Business Leadership with Two Key Promotions

May 15, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Their Buy Rating for Erasca (ERAS)

May 15, 2023 | finance.yahoo.com

Erasca Reports First Quarter 2023 Financial Results and Business Updates

May 2, 2023 | finance.yahoo.com

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

May 1, 2023 | finance.yahoo.com

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

April 26, 2023 | finance.yahoo.com

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

April 25, 2023 | finance.yahoo.com

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

April 22, 2023 | americanbankingnews.com

Erasca, Inc. (NASDAQ:ERAS) Short Interest Up 12.0% in March

April 18, 2023 | markets.businessinsider.com

Erasca (ERAS) Gets a Buy from Mizuho Securities

April 18, 2023 | ca.finance.yahoo.com

Erasca, Inc. (ERAS) Stock Price, News, Quote & History - Yahoo Finance

April 18, 2023 | finance.yahoo.com

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

April 13, 2023 | americanbankingnews.com

Alexander W. Casdin Buys 20,000 Shares of Erasca, Inc. (NASDAQ:ERAS) Stock

April 10, 2023 | markets.businessinsider.com

Mizuho Securities Remains a Buy on Erasca (ERAS)

April 10, 2023 | finance.yahoo.com

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

April 1, 2023 | americanbankingnews.com

Erasca (NASDAQ:ERAS) Earns Buy Rating from Analysts at Mizuho

March 31, 2023 | seekingalpha.com

Erasca spikes as CEO reports stock purchase

March 31, 2023 | msn.com

Mizuho Initiates Coverage of Erasca (ERAS) with Buy Recommendation

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Company Calendar

Last Earnings: 3/23/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ERAS
CUSIP: N/A
CIK: 1761918
Web: www.erasca.com
Phone: 858-465-6511
Fax: N/A
Employees: 123
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.33
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +324.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.87)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-242,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.81%
Return on Assets: -29.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.59
Quick Ratio: 15.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.57 per share
Price / Book: 1.04

Miscellaneous

Outstanding Shares: 150,590,000
Free Float: 94,118,000
Market Cap: $402.08 million
Optionable: Not Optionable
Beta: 1.10

Key Executives

Dr. Jonathan E. Lim M.D. (Age 51)
Co-Founder, Chairman & CEO
Comp: $850.23k

Mr. Ebun S. Garner J.D. (Age 51)
Esq., Gen. Counsel & Corp. Sec.
Comp: $510.98k

Dr. Wei Lin M.D. (Age 53)
Chief Medical Officer
Comp: $1M

Dr. Michael D. Varney Ph.D. (Age 65)
Chairman of R&D, Scientific Advisory Board Member and Director
Comp: $78.38k

Dr. David M. Chacko M.D. (Age 39)
Chief Financial Officer

Dr. Nik Chetwyn Ph.D.
Sr. VP of Operations

Dr. Lisa Tesvich-Bonora Ph.D.
Chief People Officer

Mr. Brian L. Baker CPA (Age 56)
M.S., MS, CPA, Sr. VP of Fin.

Ms. Chandra D. Lovejoy (Age 52)
Sr. VP of Regulatory Affairs

Dr. Robert Shoemaker Ph.D. (Age 42)
Sr. VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ERAS Stock - Frequently Asked Questions

Should I buy or sell Erasca stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ERAS shares.
View ERAS analyst ratings or view top-rated stocks.
What is Erasca's stock price forecast for 2023?: 3 analysts have issued 1-year target prices for Erasca's shares. Their ERAS share price forecasts range from $9.00 to $15.00. On average, they expect the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 324.5% from the stock's current price.
View analysts price targets for ERAS or view top-rated stocks among Wall Street analysts.
How have ERAS shares performed in 2023?: Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS shares have decreased by 38.1% and is now trading at $2.67.
View the best growth stocks for 2023 here.
Are investors shorting Erasca?: Erasca saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 10,340,000 shares, a decrease of 9.2% from the April 30th total of 11,390,000 shares. Based on an average daily volume of 924,800 shares, the days-to-cover ratio is presently 11.2 days. Approximately 12.5% of the company's stock are sold short.
View Erasca's Short Interest.
When is Erasca's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ERAS earnings forecast.
How were Erasca's earnings last quarter?: Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.02.
What ETFs hold Erasca's stock?: ETFs with the largest weight of Erasca (NASDAQ:ERAS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), Fidelity Growth Opportunities ETF (FGRO),

When did Erasca IPO?: (ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.
What is Erasca's stock symbol?: Erasca trades on the NASDAQ under the ticker symbol "ERAS."
Who are Erasca's major shareholders?: Erasca's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.88%), BlackRock Inc. (3.57%), Bank of America Corp DE (1.98%), Geode Capital Management LLC (1.01%), Renaissance Technologies LLC (0.97%) and International Biotechnology Trust PLC (0.95%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start.
View institutional ownership trends.
How do I buy shares of Erasca?: Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Erasca's stock price today?: One share of ERAS stock can currently be purchased for approximately $2.67.
How much money does Erasca make?: Erasca (NASDAQ:ERAS) has a market capitalization of $402.08 million. The company earns $-242,800,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.
How many employees does Erasca have?: The company employs 123 workers across the globe.
How can I contact Erasca?: The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com.

This page (NASDAQ:ERAS) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial